Activation of the Toll-like receptor 8 pathway increases the immunogenicity of mesenchymal stem cells from umbilical cord

Yang,Yu; Wang,Yanwen; Li,Li; Chen,Fei; Zhang,Peng

doi:10.3892/mmr.2017.6806

Activation of the Toll-like receptor 8 pathway increases the immunogenicity of mesenchymal stem cells from umbilical cord

Authors:
- Yu Yang
- Yanwen Wang
- Li Li
- Fei Chen
- Peng Zhang
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Pathology, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 19, 2017 https://doi.org/10.3892/mmr.2017.6806
Pages: 2061-2068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) are now widely used in clinical cell‑based therapy due to their characteristics of low immunogenicity, multiple differentiation potency and the capability to modulate immune responses. However, accumulated research has indicated the absence of engrafted MSCs because of the increased immunogenicity of MSCs. Toll‑like receptors (TLRs) are essential for the innate immune response and regulating the biological function of MSCs. The present study used human umbilical cord‑derived MSCs (UCMSCs) and activated the TLR8 pathway of UCMSCs to study the role of TLR8 in mediating the immune status of UCMSCs. The results demonstrated that the activation of TLR8 increased both the proliferation of peripheral blood mononuclear cells (PBMCs) isolated from healthy human volunteers and the release of lactate dehydrogenase (LDH) in supernatant from the PBMC‑UCMSCs co‑culture system. Reverse transcription-quantitative polymerase chain reaction indicated that the TLR8 agonist increased the expression of many co‑stimulatory molecules and pro‑inflammatory genes, and flow cytometry indicated that activation of the TLR8 agonist increased co‑stimulation protein levels but reduced specific surface markers, as confirmed by the part loss of stemness of UCMSCs. Finally, TLR8 increased osteocyte differentiation but had no effect on chondrocyte and adipocyte differentiation. The current study indicated the implication to TLR8 as regulators of the immunogenicity of UCMSCs.

View Figures

View References

1	Colter DC, Sekiya I and Prockop DJ: Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA. 98:7841–7855. 2001. View Article : Google Scholar : PubMed/NCBI
2	Phinney DG and Prockop DJ: Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 25:2896–2902. 2007. View Article : Google Scholar : PubMed/NCBI
3	Bassi E, Aita CA and Câmara NO: Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? World J Stem Cells. 3:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
4	Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom HJ, Kim MG, Oh KH, Ahn C and Yang J: Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl Immunol. 25:7–15. 2011. View Article : Google Scholar : PubMed/NCBI
5	Van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW and Yarmuch ML: Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 47:1634–1643. 2008. View Article : Google Scholar : PubMed/NCBI
6	Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
7	Vojtassak J, Danisovic L, Kubes M, Bakos D, Jarabek L, Ulicná M and Blasko M: Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett. 27 Suppl 2:134–137. 2006.PubMed/NCBI
8	Ankrum J and Karp JM: Mesenchymal stem cell therapy: Two steps forward, one step back. Tends Mol Med. 16:203–209. 2010. View Article : Google Scholar
9	Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R and Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 108:2114–2120. 2006. View Article : Google Scholar : PubMed/NCBI
10	Spaggiari GM, Capobianco A, Becchetti S, Mingari MC and Moretta L: Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 107:1484–1490. 2006. View Article : Google Scholar : PubMed/NCBI
11	Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell. 124:783–801. 2006. View Article : Google Scholar : PubMed/NCBI
12	Pasare C and Medzhitov R: Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol. 560:11–18. 2005. View Article : Google Scholar : PubMed/NCBI
13	Beutler B, Hoebe K, Du X and Ulevitch RJ: How we detect microbes and respond to them: The Toll-like receptors and their transducers. J Leukoc Biol. 74:479–485. 2004. View Article : Google Scholar
14	DelaRosa O and Lombardo E: Modulation of adult mesenchymal stem cells activity by toll-like receptors: Implications on therapeutic potential. Mediators Inflamm. 2010:8656012010. View Article : Google Scholar : PubMed/NCBI
15	Lombardo E, Delarosa O, Mancheño-Corvo P, Menta R, Ramírez C and Büscher D: Toll-like receptor-mediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A. 15:1579–1589. 2009. View Article : Google Scholar : PubMed/NCBI
16	Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V, et al: Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. Stem Cells. 26:279–289. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES and Scandurro AB: Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells. 26:99–107. 2008. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Bianco P, Robey PG and Simmons PJ: Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell. 2:313–319. 2008. View Article : Google Scholar : PubMed/NCBI
20	Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O and Slavin S: Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 67:1187–1194. 2010. View Article : Google Scholar : PubMed/NCBI
21	Allison M: Genzyme backs Osiris, despite prochymal flop. Nat Biotechnol. 27:966–967. 2009. View Article : Google Scholar : PubMed/NCBI
22	Li Y and Lin F: Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 120:3436–3443. 2012. View Article : Google Scholar : PubMed/NCBI
23	Hoebe K, Janssen E and Beutler B: The interface between innate and adaptive immunity. Nat Immunol. 5:971–974. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kambris Z, Hoffmann JA, Imler JL and Capovilla M: Tissue and stage-specific expression of the Tolls in Drosophila embryos. Gene Expr Patterns. 2:311–317. 2002. View Article : Google Scholar : PubMed/NCBI
25	Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X and Hoebe K: Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol. 24:353–389. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ferrandon D, Imler JL and Hoffmann JA: Sensinginfection in Drosophila: Toll and beyond. Semin Immunol. 16:43–53. 2004. View Article : Google Scholar : PubMed/NCBI
27	Gangloff M, Weber AN, Gibbard RJ and Gay NJ: Evolutionary relationships, but functional differences, between the Drosophila and human Toll-like receptor families. Biochem Soc Trans. 31:659–663. 2003. View Article : Google Scholar : PubMed/NCBI
28	Schon MP and Schön M: TLR7 and TLR8 as targets in cancer therapy. Oncogene. 27:190–199. 2008. View Article : Google Scholar : PubMed/NCBI
29	Yamamoto-Furusho JK and Podolsky DK: Innate immunity in inflammatory bowel disease. World J Gastroenterol. 13:5577–5580. 2007. View Article : Google Scholar : PubMed/NCBI
30	Huang XP, Sun Z, Miyagi Y, Kinkaid H McDonald, Zhang L, Weisel RD and Li RK: Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI